康哲药业入选2024年度“中国医药上市公司ESG竞争力”系列榜单

深圳, 2024年10月21日 - (亚太商讯 via SeaPRwire.com) - 近日,E药经理人联合中国领先的企业社会责任独立咨询机构发布2024年度"中国医药上市公司ESG竞争力"系列榜单,旨在表彰在ESG管理各方面具有标杆作用的中国医药企业。康哲药业凭借在可持续发展、低碳行动方面的不断努力,连续三年入选"中国医药上市公司ESG竞争力TOP20(中盘股)"榜单,并入选首届"中国医药上市公司低碳先锋TOP10"榜单。康哲药业作为可持续发展理念的积极践行者,切实响应联合国可持续发展目标,将ESG治理与集团宏观战略和业务运营深度融合。集团坚持高商业道德标准的运营,已构建科学有效的风险识别与管控体系,并坚持高质量创新,为各利益相关方提供专业、优质的产品和服务。同时,康哲药业切实关心员工及周边社区的发展,践行暖心捐赠、扶贫济困、关怀弱势群体等活动。康哲药业亦不断探索对生态环境影响更小的运营发展模式,从"企业治理、策略、风险管理、目标规划"等维度着手,积极推进气候风险评估、分析与应对工作,为减缓全球气候变化贡献力量。康哲药业持续推动ESG管理实践的进步,获得了全球权威ESG专业评级机构的广泛认可,其ESG表现位于全球同业前列。康哲药业明晟MSCI ESG评级维持"AA";标普全球(S&P Global)ESG评分超过全球95%的参评同业,并连续两年获入选标普全球《可持续发展年鉴(中国版)》;香港品质保证局(HKQAA)可持续发展评级位于行业前10%水平;华证指数ESG评级为"AA"。未来,康哲药业将继续坚持负责任、可持续运营,推动企业与医药行业绿色转型,以实际行动支持人类迈入可持续的繁荣发展之路。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More
国泰君安国际荣获HKQAA香港绿色和可持续金融大奬 2024多项殊荣

国泰君安国际荣获HKQAA香港绿色和可持续金融大奬 2024多项殊荣

香港, 2024年10月21日 - (亚太商讯 via SeaPRwire.com) - 国泰君安国际控股有限公司(「国泰君安国际」、「公司」或「集团」,股份代号:1788.HK)宣布,公司凭借在绿色金融服务及可持续发展领域之卓越表现,于香港质量保证局(Hong Kong Quality Assurance Agency,简称HKQAA)举办的「香港绿色和可持续金融大奬 2024」中,荣获多项殊荣﹐包括:「杰出绿色和可持续贷款发行机构(证券金融服务业)- 卓越远见可持续发展挂钩贷款绩效指标」大奖,公司董事会主席、执行董事阎峰博士荣获「杰出绿色和可持续金融发展领袖」奖项,及公司董事会办公室联席董事余欣女士获得「杰出绿色和可持续金融发展策略专才」奖项。国泰君安国际始终坚持践行金融服务实体经济的理念,积极支持和推动企业客户的绿色转型。2023年,公司参与完成的可持续金融业务发行总量超过800亿港元。同时,公司不断进行可持续发展的多元化探索,今年年初,公司与华侨银行(香港)签订了中国内地及香港地区证券行业首笔可持续发展挂钩贷款,为业界ESG发展树立了典范。此次获奖,标志着行业权威机构对国泰君安国际致力于促进自身及社会整体可持续发展实践的高度肯定。未来,公司将进一步提升在绿色及可持续金融领域的参与度及竞争力,为行业及社会可持续发展作出积极贡献。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More
Majority of Singapore Employees Comfortable Discussing Mental Health at Work, foundit Survey Reveals

Majority of Singapore Employees Comfortable Discussing Mental Health at Work, foundit Survey Reveals

Positive strides in work-life balance and mental health openness highlight progress,while workload challenges present opportunities for improvementKey findings from the survey:57% of employees report a positive work-life balance, with 37% calling it "Good" and 20% calling it "Excellent."35% are actively using wellness programs, reflecting growing engagement in well-being initiatives.46% rarely or never experience burnout, though 37% occasionally face it, highlighting areas for support.66% report heavy workloads, pointing to the need for better workload management.SINGAPORE, Oct 21, 2024 - (ACN Newswire via SeaPRwire.com) - A recent survey by foundit, a leading jobs and talent platform, highlights encouraging developments in Singapore's workplaces. The study reveals that 57% of employees rate their work-life balance as "Good" or "Excellent," and 51% feel comfortable discussing mental health issues with their managers or HR.These findings reflect a growing emphasis on employee well-being and a more open dialogue around mental health in the corporate environment.However, despite these positive trends, the survey also uncovers areas that warrant attention. A significant 66% of employees report heavy workloads, suggesting room for improvement in workload distribution and management.Additionally, while 35% of respondents are engaging with wellness programs, a notable portion of employees have not yet utilised these resources, which may impact their ability to manage stress effectively.As a result, 37% of employees occasionally experience symptoms of burnout, such as exhaustion or reduced professional efficacy. This underscores the need for continued support and resources to help employees cope with workplace demands.Sekhar Garisa, CEO of foundit, commented on the survey:"It's heartening to see that a significant number of employees in Singapore are enjoying a positive work-life balance and feel comfortable discussing mental health at work. This marks a substantial step forward in creating supportive workplace cultures. While there are areas that warrant attention, such as workload management and addressing burnout, the overall findings are encouraging. By continuing to focus on employee well-being, Singaporean businesses can enhance productivity, foster innovation, and maintain their position as leaders in the global economy."Key Survey Highlights: Building on Positive MomentumThe survey underscores the progress made in Singapore's corporate sector and identifies opportunities for further enhancement:Work-Life Balance: 57% of employees report a positive work-life balance—37% rating it as "Good" and 20% as "Excellent". By supporting the 43% who rated their balance as "Fair" (27%) or "Poor" to "Very poor" (16%), organisations can further promote harmony between professional and personal lives.Increasing Mental Health Openness: A significant 51% of employees feel comfortable discussing mental health issues with their manager or HR, comprising 23% who are "Very comfortable" and 28% who are "Comfortable."Wellness Program Engagement: While 35% of respondents have utilised employee wellness programs, there's an opportunity to reach the 38% who haven't yet participated and the 27% who are unaware of such initiatives.Workload Management: 66% of employees report heavy workloads (42% "Heavy" and 24% "Extremely heavy"), giving organisations a chance to improve workload distribution.Addressing Burnout: Encouragingly, 46% of employees rarely or never experience burnout symptoms (24% "Never," 22% "Rarely"). Organisations need to support the 37% who occasionally face challenges.Key Stress Factors: Employees identify workload (37%), and lack of support (34%) as the top contributors to work-related stress. Addressing these areas offers organisations a clear focus for enhancing employee satisfaction and reducing stress.Looking AheadSingapore's workplaces have made notable strides in fostering environments that support employee well-being. By addressing areas that need attention and building upon the positive trends identified, organisations can create even more supportive and productive workplaces.As Singapore continues to evolve as a global business leader, emphasising employee well-being will contribute to sustained economic growth and social development. The findings from foundit's survey not only celebrate progress but also serve as a roadmap for continued improvement.By providing valuable insights into current workplace dynamics, the survey equips organisations with the information needed to implement effective strategies that enhance employee well-being and productivity.About foundit - APAC & Middle Eastfoundit, formerly Monster (APAC & ME) is Asia’s leading jobs and talent platform offering comprehensive employment solutions to recruiters and job seekers across APAC & ME. In addition to a powerful AI-powered job search, foundit offers e-learning, assessments, and services related to resume creation, interview preparation, and professional networking. Since its inception, the company has assisted over 120 million job seekers across 18 countries in upskilling and connecting them with the right job opportunities. foundit is now also the Official Talent Partner of the Badminton World Federation across 20 key world tour events. Over the last two decades, the company has been a leader in the world of recruitment solutions and has recently launched a cutting-edge solution to give recruiters access to passive candidates in addition to active ones. With the use of advanced technology, foundit is seeking to efficiently bridge the talent gap across industry verticals, experience levels, and geographies.Today, foundit is committed to enabling and connecting the right talent with the right opportunities by harnessing the power of deep tech to sharpen hyper-personalised job searches and offer precision hiring.To learn more about, foundit in APAC & Gulf, visit:Singapore: https://www.foundit.sgPhilippines: https://www.foundit.com.phMalaysia: https://www.foundit.myIndia: https://www.foundit.inGulf: https://www.founditgulf.comHong Kong: https://www.foundit.hkIndonesia: https://www.foundit.idContact:For media inquiries or further information, please contactNamrata Sharma – Namrata.sharma@adfactorspr.comContact number - +65 81383034 Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Learn & Get Inspired at the Global STEM Confex

Learn & Get Inspired at the Global STEM Confex

DUBAI, UAE, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - The Global STEM Education Confex is back for its 11th edition, hosted by IBEForuM, happening on 6-7 November 2024 promises to be an unparalleled platform for knowledge exchange, collaboration, and innovation among educators, researchers, policymakers, and industry leaders. Set against the backdrop of the stunning Millennium Plaza Downtown Hotel in Dubai, this premier event is designed to connect thought leaders and drive the future of STEM education.This year’s Confex will gather top-notch speakers from around the globe, including 29 distinguished speakers and representatives from education ministries. With over 500+ delegates expected to attend from various countries, the conference is set to be a vibrant hub of ideas and solutions. The event is supported by 26 media partners and 22 sponsors, from across the globe with more to be announcedEvent Highlights:Engage with Policymakers and Industry Leaders: Collaborate to align STEM education with industry needs, ensuring a workforce equipped for future challenges.Hands-on Workshops and Interactive Labs: Participate in immersive sessions that provide practical insights and applicable skills in STEM education.Global Collaboration Opportunities: Network with educators, researchers, and innovators from around the world to discover potential partnerships.Explore Cutting-edge Advancements: Stay informed about the latest technologies and educational tools transforming STEM learning.Join us for this prestigious event, where STEM education and innovation meet to create lasting global impact. We look forward to welcoming you to Dubai!Event Details:Date: 6-7 NovemberVenue: Millennium Plaza Downtown Hotel, Dubai, UAEAbout IBEForuMIBEForuM is an International Organization with the goal of empowering global leaders to carve a better future. We are here to solve our shared global challenges through the power of collaboration. We help your business to build a sustainable future by synergizing ideas and infusing innovative solutions. Our insights and quality services help build trust and confidence giving birth to a ground-breaking alliance between academic research and practitioners thus helping them excel in this era of the digital revolution.Our extensive cross-industry connections bring together high calibre, industry leaders to provide the latest policy updates, strategic insight, and practical guidance. We deliver a broad range of industry-specific services that help create valuable relationships between our clients, their customers, employees, and regulatory authorities. We drive transformation by leveraging our cross-functional expertise across various domains. For more information, visit www.ibeforum.com.Speaking and Sponsorship Opportunities:For those interested in contributing to this significant event:Speaking Opportunities:Contact Arif Ulla+91 9845-113-293Email - arif.ulla@ibeforum.com Sponsorship Opportunities: Reach out to Imroze Shaik +91 9901-955-118Email - imroze.shaik@ibeforum.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More

Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy

SHANGHAI, Oct 21, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON® indicated “to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression1”. There are no restrictions on initial proteinuria levels in the approved indication. This marks the expansion of NEFECON®, the world's first and only IgAN etiological treatment drug fully approved by the U.S. Food and Drug Administration (FDA), to more IgAN patients."The approval of NEFECON® in Taiwan, China is another milestone for NEFECON®, following approvals in Singapore, Hong Kong, and the commercial launch in Mainland China this year.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “IgAN is prevalent in the Asian population, which has 56% higher risk of progression to end-stage renal disease and faster disease progression, indicating a significant unmet clinical demand. In the future, we will continue to expand the access of NEFECON® across Asia to bring this first-in-disease therapy to more patients."The global Phase 3 NefIgArd clinical trial showed that compared to placebo, NEFECON® not only brought about a sustained reduction in proteinuria and reduced the frequency of microscopic hematuria but also demonstrated clinically relevant and statistically significant treatment benefits in estimated glomerular filtration rate (eGFR) (p
More
Ching Lee Holdings practices CSR to promote sustainability in the construction industry

Ching Lee Holdings practices CSR to promote sustainability in the construction industry

HONG KONG, Oct 21, 2024 - (ACN Newswire via SeaPRwire.com) - With the increasing global emphasis on sustainability, the Hong Kong government has introduced the 'Hong Kong's Climate Action Plan 2050'. To enhance the transparency of environmental governance and climate-related disclosure for listed companies, HKEX has also revised the "ESG Code" to be effective from 1 January 2025. Within this evolving framework, Corporate Social Responsibility (CSR) and Environmental, Social, and Governance (ESG) factors have emerged as pivotal foundations for business development. This is particularly evident in Hong Kong's construction industry, where numerous companies proactively champion these initiatives to demonstrate a steadfast commitment to a sustainable future.As a good model among Hong Kong listed companies in construction industry, Ching Lee Holding Limited (3728. HK) is advancing its ESG agenda through a variety of initiatives. Notably, Ching Lee participated in the "ESG Pledge Scheme" this year organised and recognised by The Chinese Manufacturers' Association of Hong Kong. This initiative reinforces Ching Lee's leadership role in promoting ESG principles and highlights its proactive stance on sustainability.Employees' welfare and occupational health and safety are always the most important items on the ESG agenda. Ching Lee ensures preparedness on construction sites and conducts emergency drills regularly. This dedication reflects its responsible commitment and a profound respect for employee safety. Moreover, the company places a high value on enhancing employee skills. According to Ching Lee's annual report, the total training hours for employees reached an impressive 98.5 hours, with a training participation rate of approximately 60%. Employees are also integral participants in the ESG framework. Several companies have established training systems that align employee development closely with corporate sustainability objectives, thereby achieving a mutually beneficial outcome.In addition to prioritising occupational safety and skills training, Hong Kong companies support public welfare projects in education, healthcare, and culture, while encouraging employees to engage in community service. According to the annual report from Ching Lee Holdings, the company donated over HKD 1.5 million to various charitable organisations in the 2023-2024 financial year, with more than 60 employees actively participating in community service. Furthermore, Ching Lee commits to promoting green building technologies and mandates that all employees adhere rigorously to environmental standards throughout construction. For instance, the company advocates for using recyclable building materials and strives to minimise waste generation during construction activities in addition to energy-saving and emission-reduction measures.By implementing a comprehensive range of initiatives, Hong Kong companies enable their workforce to become active participants in ESG efforts. Ching Lee Holdings adeptly links corporate development with employee growth, illustrating that corporate social responsibility is not merely essential but constitutes a fundamental pillar of sustainable development. Copyright 2024 ACN Newswire via SeaPRwire.com.
More

云顶新耀宣布中国台湾地区药政部门批准全球首个对因治疗IgA肾病药物耐赋康®的新药上市许可申请

上海, 2024年10月21日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀(HKEX 1952.HK)是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司,今日宣布,中国台湾地区药政部门(TFDA)已批准耐赋康®(布地奈德肠溶胶囊,NEFECON®)用于治疗罹患原发性免疫球蛋白A肾病变(IgA nephropathy)且病情有进展风险的成人病人,用以延缓肾功能下降1 ,且无基线蛋白尿水平限制。这意味着耐赋康®作为全球首个且唯一获得美国食品药品监督管理局(FDA)完全批准的IgA肾病对因治疗药物,其覆盖范围进一步扩大,为更多中国IgA肾病患者带来了新的希望。云顶新耀首席执行官罗永庆表示:"耐赋康®在中国台湾的获批,是今年耐赋康®继在新加坡、中国香港获批以及中国大陆首张处方落地之后的又一里程碑。在IgA肾病患者中,亚洲人群进展为终末期肾病的风险相较于其他人群高56%,且疾病进展更快,因此存在巨大未被满足的临床需求。未来,我们将继续扩大耐赋康®在亚洲地区的可及性,以更好地满足中国乃至亚洲更多IgA肾病患者迫切的临床需求。"NefIgArd 3期全球临床试验结果显示:与安慰剂相比,耐赋康®不仅带来了持久的蛋白尿下降,减少镜下血尿风险,更重要的是在估算肾小球滤过率(eGFR)上显示出临床相关且有统计学意义的治疗获益(p
More
正利控股推动建筑业可持续发展与企业社会责任实践

正利控股推动建筑业可持续发展与企业社会责任实践

香港, 2024年10月21日 - (亚太商讯 via SeaPRwire.com) - 随著全球对可持续发展的重视,香港政府公布《香港气候行动蓝图 2050》,联交所先后修订,并将于2025年1月1日实施《ESG守则》,旨在加强上巿公司的环境管治及气候信息透明度。在这一背景下,企业社会责任(CSR)及环境、社会及治理(ESG)已成为企业发展的重要基石,尤其是在香港的建筑行业中,许多企业正积极推动这些努力,以展现对可持续未来的坚定承诺。首先,在職業健康與安全方面,許多公司始終將僱員的安全放在首位。例如,香港主板上市的建築公司正利控股有限公司(3728.HK),正在通過各種舉措推動企業社會責任和可持續發展。正利控股本年度參加了由香港中華廠商聯合會主辦的「ESG 約章」行動,獲得了第三方權威機構的認可。此舉旨在鞏固其在推廣和實踐ESG方面的領導地位。正利還承諾在未來降低工程及辦公室的能源消耗,並大力推動辦公室無紙化及內部環保政策。這不僅增強了企業的內部能力,還能在環保意識不斷提升的市場中贏得競爭優勢,推動企業的長期可持續發展。在工地场所,正利控股致力于提供安全的工作环境,并在建筑工地定期进行应急演练。这不仅是企业的责任,更是对员工生命安全的尊重。此外,公司还重视增强雇员技能,培养未来的领袖。根据该集团年度报告的数据,雇员的培训总时数达98.5小时,参训比例高达约六成。这样的培训不仅提升了员工的专业技能,更让员工意识到自身在社会环境中的重要角色。因为员工不仅是企业的生产力,更是环境保护和社会责任的参与者。某些公司在这方面的培训体系,将员工的发展与企业的可持续发展目标紧密联系在一起,从而达到双赢的效果。正利控股在推广绿色建筑技术方面也不遗馀力,公司要求所有员工在施工过程中严格遵守环保标准。例如,正利控股提倡使用可回收的建筑材料,并在施工过程中最大限度地减少废弃物产生。此外,该公司还积极推广节能减排措施,如使用节能灯具和电动设备,以降低能源消耗。除了职业安全和技能培训,企业在员工ESG方面还有其他举措。例如,许多公司支持教育、医疗和文化等公益事业,并鼓励员工参与社区服务。根据正利控股的年报数据,该公司在2023-2024财年向多个公益机构捐赠超过150万港元,并有超过60名员工参与社区服务,这些行动彰显了企业的社会参与。总体而言,对于环境及社会的探索之路,不仅仅是企业的责任,更是企业对员工的尊重和赋能。通过一系列的举措,企业让员工成为ESG的参与者,正利控股将企业的发展与员工的成长紧密联系在一起。这不仅是企业社会责任的体现,更是可持续发展的基石。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More
Moolec Has Received USDA Approval for the First Genetically Modified Pea in History

Moolec Has Received USDA Approval for the First Genetically Modified Pea in History

Luxembourg, Oct 16, 2024 - (ACN Newswire via SeaPRwire.com) - Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance from USDA-APHIS achieved by Moolec in an 18-month window, alongside its genetically engineered safflower and soybean for GLASO™ and Piggy Sooy™ products, respectively. Access the official USDA-APHIS publication here."With USDA approval for our GE pea, Moolec has now secured regulatory clearance for all of our key crops in the US: safflower, soybean, and pea," said Gastón Paladini, CEO and Co-Founder of Moolec. "We are proud to be the only Molecular Farming company with three US regulatory approvals and a major commercial contract. This milestone underscores our leadership in the landscape with tangible, science-backed results."Moolec's genetically engineered peas produce high yields of bovine myoglobin, a protein that boosts iron content, making it an ideal alternative for consumers seeking plant-based sources of iron. This product has the potential to revolutionize both the food ingredient market and the $65 billion pea industry by offering a nutritious, iron-rich alternative to traditional meat products.Amit Dhingra, Chief Science Officer for the Company, stated, "The USDA-APHIS Regulatory Status Review for pea marks a significant milestone for Moolec. As the first review for GE pea, it represents a historic development. It validates Moolec's strategic approach and exemplifies our commitment advancing sustainable food production through science and innovation. This approval is a critical step toward enhancing global food supply and meeting the growing demand for innovative, nutritious food solutions for the world."This approval not only showcases Moolec's innovation in Molecular Farming but also highlights the company's commitment to meeting the highest regulatory and safety standards. Moolec has also developed an Identity Preservation Program to ensure sustainable farming practices, promote stewardship for its crops and product quality for partners, clients and consumers alike.According to USDA-APHIS regulation found at 7 CFR part 340, developers may submit a request for a RSR when they believe a GE plant is not subject to the regulation. APHIS reviews the GE plant and considers whether it might pose an increased plant pest risk compared to its non-GE comparator. If APHIS does not identify a greater pest risk relative to the comparator, the GE plant is not subject to this regulation. Regulation 7 CFR part 340 governs the importation, interstate movement, and the environmental release of certain organisms that have been modified or produced by genetic engineering.The USDA-APHIS review process is a critical component of ensuring that genetically engineered crops can be grown safely, and this approval opens the floor for expanded field trials, seed scaling, and eventual commercialization. With increasing interest in science-based ingredients, this approval positions the company to lead a new wave of innovation in the food and agriculture sectors.About Moolec Science SAMoolec is a science-based ingredient company leader in the use of Molecular Farming technology for food and dietary supplementation markets. The Company's mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal proteins for the good of the planet. Moolec's technological approach aims to have the cost structure of plant-based solutions with the nutrition and functionality of animal-based ones. Moolec's technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company's product portfolio and pipeline leverage the agronomic efficiency of broadly used target crops like soybean, pea, and safflower to produce oils and proteins. Moolec also has an industrial and commercial R&D capability to complement the company's Molecular Farming technology. Moolec secures a growing international patent portfolio (25+, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of PhDs and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit moolecscience.com and ir.moolecscience.com.Forward-Looking StatementsThis publication contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this publication, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this publication will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Contact InformationPress & Mediacomms@moolecscience.comInvestor Relationsir@moolecscience.comRelated FilesMoolec Has Received USDA Approval For The First Genetically Modified Pea In HistorySOURCE: Moolec Science Copyright 2024 ACN Newswire via SeaPRwire.com.
More
CITIC Telecom CPC Propels ‘+AI to AI+’

CITIC Telecom CPC Propels ‘+AI to AI+’

HONG KONG, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is at the forefront of AI+ innovation era, enabling dual empowerment of technology and data, and fostering a new business model of intelligence and innovation across industries. CITIC Telecom CPC has further unleashed multiple AI+ projects powered by “AI+ Cloud, Network, Security” framework, the integration of AI technology with big data analytics and security capabilities, and vital customer experience, fueling innovative AI+ applications across industries to reshape the Intelligence Operation Journey of enterprises.CITIC Telecom CPC collaborates with partners to co-create AI+ EcosystemFrom “Technology Empowerment”(+AI) to “Data Empowerment” (AI+)AI has become a cornerstone in today’s business landscape. As a leading Global-Local Intelligent DICT Service Partner, CITIC Telecom CPC fully embraces the global digitalization era and proactively deploys the visionary “ICT-MiiND” framework. This framework seamlessly integrates an “innovative” technology stack, the power of algorithms and big data into the ICT service platform, spanning across “Cloud, Network, Security” and bolstering the element of “intelligence” through cutting-edge AI technology and AIOps modules. CITIC Telecom CPC believes in the transformative power of AI+, actively enhances the in-depth integration of AI across various industries, driving innovative projects from focusing on "Big Data Modelling" to "Small-Scale Scenario implementation". CITIC Telecom CPC has not only deployed extensive resources in AI technologies, but also deeply integrated generative AI applications across the full-chain technology modules, evolving from Technology Empowerment (+AI) to Data Empowerment (AI+), ushering in a new era driven by AI algorithms and big data. AI+ covers diverse AI technologies and applications, integrating big data platforms with small-scale scenario models. This approach covers data collection, storage, governance and mining through deep algorithms, machine learning, and intelligent analysis, to develop a range of intelligent applications and AI+ solutions. Tailored to meet enterprise needs, it provides a one-stop service from business transformation to strategic analysis, efficiently fulfilling enterprise requirements.“CITIC Telecom CPC strives to integrate large AI models with diverse AI+ applications in small-scale scenarios, empowering customers to advance intelligent capabilities, unlocking a realm of new possibilities,” said Mr. Brook Wong, CEO of CITIC Telecom CPCMr. Brook Wong, Chief Executive Officer of CITIC Telecom CPC, said, “Striding from +AI to AI+, CITIC Telecom CPC pioneers AI technologies with a steadfast commitment to ‘Innovation Never Stops', continuously optimizes “Cloud, Network, Intelligence, Security” "solutions, and accelerates the development of intelligence-enabled industries. We actively dedicate various resources and collaborate with partners to co-create a prosperous AI+ ecosystem, enrich technical infrastructure, lead our team and the industry towards a generative AI era driven by large language models, AI technologies, data and intelligent analysis. We strive to integrate large AI models with diverse AI+ applications in small-scale scenarios, empowering customers to advance intelligent capabilities, unlocking a realm of new possibilities.”Transformative AI+ Solutions Generate New Driving Force for Data & Security ApplicationsCITIC Telecom CPC stands at the forefront of AI technology. With decades of ICT experience and industry expertise, its data science and innovation teams are propelling AI innovations with cutting-edge algorithms and deep learning techniques, unlocking data value and accumulating a range of generative AI applications for enterprises. The team has developed a series of award-winning and groundbreaking AI+ solutions such as the newly-launched AI Databank and AI Pentest, driving operational efficiency and cost savings for enterprises.AI Databank – Powering Big Data with Fast, Accurate & Actionable Insights on a Single PlatformAI Databank integrates tremendous data from various business systems, collecting a wide array of internal and external information (such as CRM and ERP). Utilizing generative AI technology, enhanced by deep learning and big data training, it enables efficient data management and real-time report generation. Users can interact with the platform to quickly retrieve data and multiple real-time data charts through dialog-based data queries, empowering data-driven decision making. AI Databank also analyzes current and historical data to build forecast models, helping companies in future planning.AI Pentest – Redefining Vulnerability Assessment with Proactive, Secure and Intelligent AutomationCITIC Telecom CPC has successfully led the Security Operations Center (SOC) to enter into a new AI-driven era since the launch of "TrustCSI™ 3.0" cybersecurity solution at the end of last year. The newly-launched AI Pentest plays a key role in the security portfolio. It is a lightweight solution powered by unique AI-driven bypass techniques to expose WAF vulnerabilities, enabling automated routine task scheduling to simplify the assessment of internal network asset and empower enterprises to keep pace with the rapidly changing IT environment. AI Pentest functions as an AI robot cleaner which automatically operates 24x7, helping enterprises identify key vulnerabilities in the network and establish a robust defense against potential threats.CITIC Telecom CPC's AI+ solutions have been implemented in various industries to foster integration of diverse AI+ applicationsAI+ Reshapes Industries with New Scenarios & Business ValuesCITIC Telecom CPC's AI+ solutions have been implemented in various industries to foster integration of diverse AI+ applications, assisting customers in incorporating generative AI technology, deep learning and data applications, empowering digital transformation for enterprises including:- AI+TelecommunicationsCITIC Telecom CPC leverages AI+ innovation capabilities to create a "Network and Information Security Threats Identification Algorithm Model". Leveraging Natural Language Processing (NLP), algorithm models and innovative technical architecture, an "AI+ telecommunications industry" application platform is created. The platform uses large AI security industry models to learn and identify scams as well as the patterns and characteristics of fraudulent calls. A repetitive learning and training cycle, integrated deep learning capability, on a large amount of known scams and fraudulent calls data is conducted to automatically identify new suspicious calls in the network immediately, greatly improving the accuracy of analysis and interception, and generating values for the society.Use case: Developed by CITIC Telecom, “AI+ Digital and Intelligent Cross-border Mobile Network Security Service Platform” project has won multiple distinguished awards in the market. The project utilizes Voice/Signaling/SMS firewall interception to help major telecommunications service providers, mobile service operators and enterprise sector to enable real-time alerts and interception of illegal and fraudulent Voice/SMS messages. The cloud-based platform can be utilized in local and cross-border cross-network scenarios to identify SMS messages from international countries to mainland China and inter-country communications. The solution effectively helps citizens identify registered SMS senders to stop fraudsters from sending scam SMS messages masquerading as other companies or organizations.- AI+ ManufacturingAs the global manufacturing industry is booming rapidly, the integration with different new technologies is accelerating. Powered by AI, enterprises actively deploy multiple AI tools, diverse application scenarios and big data to build an innovative digital and intelligence ecosystem. Industry chain not only enhances production efficiency and quality, but also responds to changes efficiently through digital planning and intelligent analysis, and also devises more precise future operations plans. AI-driven data security solutions provide enterprises with instant responses to security threats,enhanced data and cyber security, secure and intelligent manufacturing environment, elevating intelligent production to a new level.Use case: CITIC Dicastal, the first lighthouse factory in the global aluminum wheel industry, paved the way for its transformation journey with pivotal support from CITIC Telecom CPC and its subsidiary China Entercom in establishing a secure, efficient and fast data highway. This initiative enabled seamless connectivity among its global factories and significantly enhanced its digital and intelligent operational management capabilities. Leveraging its industry expertise, insights and technical knowledge, CITIC Telecom CPC’s Innovation team empowered CITIC Dicastal to overcome networking and security challenges across various application scenarios, including AI-driven manufacturing, process optimization, R&D design, operational decision-making, green and low-carbon initiatives, facilitating to build a “Vertical Industry Big Model of Aluminum Automobile Parts”, enhancing production efficiency and intelligence. CITIC Telecom CPC’s “AI+ Cloud, Network, Security” not only empowers the intelligent enhancement of CITIC Dicastal's entire industry chain but also reinforces its "AI+ Security" capabilities, refines real-time response alerts and develops interconnection across global factories while effectively monitoring information security threats. These initiatives strengthen the cornerstone of information security, forging a new era for the “Lighthouse Factory”. - AI+ AutomobileDemand forecasting is the most important part of the digital and intelligent transformation of an enterprise's supply chain. CITIC Telecom CPC's "Intelligent Order Demand Forecasting Solution" utilizes AI technology to predict complex and fragmented materials, improving the forecasting accuracy of order demand for vehicle models, and dynamically adjusting materials and production capacity planning.Use case: Headquartered in Europe, a world-renowned automobile parts supplier operates in 29 countries and regions, and serves various well-known automobile brands around the world. CITIC Telecom CPC’s "Intelligent Order Forecast Solution" enables customers to increase forecast accuracy to over 80%, optimize supply chain management, and achieve cost reduction and efficiency improvement.- AI+ RetailThe retail industry is undergoing a large-scale implementation of AI applications. CITIC Telecom CPC's “Cloud, Network, Intelligence, Security” integrated platform help enterprises build a secure, efficient and flexible digital infrastructure, enhance network transmission, information security, cloud computing resources and AI platform capabilities through dynamic perception, predictions and intelligent alerts for networks and applications. Harnessing AI technology and data analysis, we facilitate enterprises in expediting their digital transformation. By enhancing traditional workflow designs with scenario templates like customer service management, R&D evaluation, and marketing reports, strategically utilize big data to reinvent business to seize market opportunities.Use case: A world-renowned cosmetics retail brand has been committed to scientific research and innovation for many years. CITIC Telecom CPC's “AI+ Cloud, Network, Security” integrated platform helps to build a secure, efficient and flexible digital infrastructure. The dynamic perception of networks and applications, predictions and intelligent alerts for networks and applications assist the cosmetics retail brand to realize the values of “In Shanghai, For China, and Connect the World" to meet the needs of consumers in mainland China and around the world.To know more information aboutFrom “Technology Empowerment” (+AI) to “Data Empowerment” (AI+),please visit https://www.citictel-cpc.com/en-hk/ict-miindAbout CITIC Telecom CPCWe are CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT™ private network solutions, TrustCSI™ information security solutions, DataHOUSE™ cloud data center solutions, and SmartCLOUD™ cloud computing solutions.With the motto “Innovation Never Stops,” we leverage innovative technologies to boost technology empowerment (+AI). Embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies we aim to unlock technical potential. By integrating deep learning and intelligent data analysis technologies, we transform these technologies into data empowerment (AI+) generative applications, reshaping the Intelligence Operation Journey of enterprises.With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across nearly 160 countries and regions, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect nearly 170 points of presence (POPs), 60+ SDWAN gateways, 21 Cloud service centers, 30+ data centers, and three dedicated 24x7 Security Operations Centers (SOCs). We are certified with a series of international certifications, including SD-WAN Ready, ISO 9001, 14001, 20000, 27001, and 27017, to ensure our services compliance with international standards and resources for enterprises. We offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers.For more information, please visit www.citictel-cpc.comMedia Contacts:Catherine YuenCITIC Telecom CPC(852) 2170 7536Email: catherine.yuen@citictel-cpc.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More
中信国际电讯CPC 成就“+AI到AI+” 实现“技术赋能” 结合“数据赋能”

中信国际电讯CPC 成就“+AI到AI+” 实现“技术赋能” 结合“数据赋能”

香港, 2024年10月18日 - (亚太商讯 via SeaPRwire.com) - 中信国际电讯集团有限公司(「中信国际电讯」,香港交易所股份代号:1883)全资拥有的中信国际电讯(信息技术) 有限公司(「中信国际电讯CPC」) 站在 AI+ 创新发展前沿,实现技术与数据双赋能 ,推动产业链智能化升级新模式。中信国际电讯CPC进一步启动多个人工智能+项目落地,通过智能化升级'智赋云网安'底座;汇聚AI 技术、 大数据分析及信息安全交互能力,深入行业场景,融合智能应用赋能千行百业,重塑企业智能运营之旅。中信国际电讯CPC 携手伙伴共筑AI+ 生态圈从'技术赋能(+AI)'到'数据赋能(AI+)'人工智能(AI)在现今商业环境不可或缺,作为全球化数智通讯服务供应商,中信国际电讯CPC前瞻部署了面向未来的创新策略 'ICT-MiiND / ICT-智赋'。更将'创新'技术、算力算法和大数据元素全栈无缝融合到ICT服务平台中,全面拥抱全球生成式AI时代,夯实智赋云网安。中信国际电讯CPC深信AI+的变革力量,积极投入AI技术和AIOps模块增强'智能'元素,聚焦从'大模型建设'到'小场景落地'能力,提升与各行业深度融合。中信国际电讯CPC不仅部署了丰富的AI技术资源,更通过深度整合生成式AI应用开发的全链条技术模块、实践由技术赋能(+AI )数智化应用模式,演化成数据赋能(AI+)新篇章。AI+不但涵盖多元 AI 技术及应用,更融合大数据平台与小场景模型;从数据收集、存储、治理、挖掘,通过深度算法、机器学习与智能分析,提炼出一系列数智应用场景与AI+ 解决方案。围绕企业需求适配,提供从业务转型到战略解码,再到运营提升的一站式服务,全方位满足企业需求。中信国际电讯CPC行政总裁黄政华先生表示:「中信国际电讯 CPC致力将AI大模型与多元AI+应用小场景应用融合,助力客户创增数智动能,实现更多可能!」中信国际电讯CPC行政总裁黄政华先生表示:「从+AI到AI+新模式,中信国际电讯CPC作为业界AI技术先行者,一直秉持'创新‧不断'研发多元智能技术,持续优化'云网智安'解决方案,提速数智化赋能产业发展。我们积极投放资源,携手伙伴共筑繁荣AI+ 生态圈,丰富技术底座,引领客户及行业走向以大语言模型、AI技术、智能分析及数据驱动的生成式AI年代;致力将AI大模型与多元AI+应用小场景应用融合,助力客户创增数智动能,实现更多可能!」变革性的AI+解决方案 赋予数据及信息安全应用场景新动能中信国际电讯CPC站在AI技术的前沿,凭借二十多年ICT的专业经验和行业知识, 其数据科学和创新团队在人工智能领域持续发力,以创新算法及深度学习技术释放数据价值,更积累了大量生成式AI案例在企业端应用实践,为企业降本增效。一系列屡获殊荣的AI+解决方案中包括最新的AI Databank (智数库)及AI Pentest (渗透测试)。- AI Databank (智数库) - 大数据平台、智能化分析 | 更快、更准、更科学AI Databank (智数库) 通过整合多个系统,收集内外信息 (如客服管理及运营日志等)的海量数据,利用生成式AI技术,经过深度学习与大数据训练,提供数据管理,即时生成报表。并可通过大型语言模型技术驱动的智慧分析功能,让用户以对话式界面与平台互动,快速检索资料及生成各种可视化图表,从而提炼数据驱动的商业价值。此外,更可通过分析当前及历史数据,构建预测模板,助力企业规划未来。- 革新自动AI Pentest (渗透测试) | 更主动、更安全、更智能中信国际电讯CPC自去年底推出的'TrustCSI™ 3.0云网神盾'网络安全解决方案,成功引领安全运作中心(SOC)进入AI驱动的新时代。最新的AI Pentest渗透测试,更在整个方案中发挥关键作用。AI渗透测试是一项轻量级解决方案,采用独特的 AI驱动技术,有效揭示网站应用程序防火墙(WAF)的弱点,并实现自动化的例行任务调度,以简化内部网络资产漏洞评估流程。AI渗透测试如同网络AI扫地机器人,7x24全自动化运作,协助企业找出网络中的关键漏洞,建立强大的主动式防御机制。中信国际电讯CPC的AI+方案落地于千行百业,推动AI+应用向多元场景发展AI+数智化产业新模式 为千行百业创优增值中信国际电讯CPC的AI+方案落地于千行百业,推动AI+应用向多元场景发展,协助产业链将生成式AI技术,深度学习及数据应用全栈融合业务,为企业数字化转型之旅赋能,当中包括:- AI+电讯业中信国际电讯CPC以AI+创新能力打造「网络与信息安全威胁识别算法模型」,凭借自然语言处理,算法模型,与创新技术架构,构建'AI+电讯产业'应用平台,利用人工智能安全行业大模型学习和识别骚扰,以及诈骗电话的模式与特征 ,对大量已知骚扰及诈骗电话资料进行预学习,知识解构和深度训练,自动学习识别网络中即时出现新的骚扰或诈骗电话,大幅提高分析及拦截准确率,为社会缔造价值。用户个案: 中信国际电讯自主研发的'AI+跨境移动通信网络安全管理平台'项目,获得市场上多个重量级奖项。项目通过提供语音/信令/短信防火墙拦截,助力各主要电讯业界、移动服务运营商及企业客户实时预警及拦截非法欺诈语音/短信。平台采用云端架构 ,应用于本地及跨境跨网场景,识别从国际到中国内地、国际与国际之间的通讯,方案有效协助市民识别已获认证的短信发送人,以打击涉及冒充其他公司或机构身份发出短信行骗。- AI+制造业制造业全球发展迅速,与新技术融合的动力与日俱增,在AI的引领下,企业积极综合运用多种AI 工具、多元应用场景和大数据等创新技术,构建革新数智化生态系统。产业链不仅提高生产效率和质量,通过数字规划和智能分析,能高效响应变化,并可更精准做好未来运营规划。加持AI驱动信息安全解决方案,更为企业安全威胁监测提供即时响应,加强数据及信息安全保障,锻造出更安全、更智能的制造环境,助力智能生产领域全面升级。用户个案:中信戴卡是全球铝车轮行业首家'灯塔工厂',在其数智化建设过程中,中信国际电讯CPC联同子公司中企通信扮演了至关重要的角色,为其搭建了安全、高效、快速的数据高速公路,网络不仅覆盖了广泛的国际区域,还有效地促进了中信戴卡全球各工厂之间的互联互通,并助力其显著提升了数智化运营管理水平。创新团队凭借深厚的行业洞察与技术实力,助力中信戴卡在AI视觉赋能制造、AI赋能工艺优化、AI赋能研发设计、AI赋能运营决策、AI赋能绿色低碳等多个应用场景克服网路和安全等方面的挑战,助力构建'铝制汽车零部件垂直行业大模型',进一步提高了生产效率和智能化水平。智赋云网安平台不仅为中信戴卡的全产业链智能升级提供了有力保障,更夯实了其'AI+安全'能力,通过自动化威胁监测与高效实时的回应警报,筑牢信息安全底座,锻造'灯塔工厂'新辉煌。- AI+汽车业需求预测是企业供应链数字化、智能化转型布局中的重要一环。中信国际电讯CPC'订单需求智慧预测专案解决方案',应用AI技术为零散物料供应链提供精准数据分析,提升车型订单需求的预测准确率 ,动态调节物料及产能规划。用户个案:总部位于欧洲的世界知名的汽车零件供应商,业务分布在29个国家地区,服务全球众多知名汽车品牌。中信国际电讯CPC赋能客户打造'订单需求智慧预测专案解决方案',提升预测准确率达80%以上,优化供应链管理, 实现降本增效。- AI+零售零售业处于人工智能大规模落地的应用水平。中信国际电讯CPC一体化'云网智安'解决方案协助企业构建安全、高效及灵活的数智基础设施,更通过对网络及应用的动态感知、预测及智慧预警,提升网络传输、信息安全、云端运算资源及AI平台的能力。配合AI技术与数据分析助力企业提早数智化部署,在传统工作流设计模式的基础上增加场景模版,如客服管理、研发评审和营销报告等场景,利用大数据规划策略以赢得市场先机。用户个案:国际知名化妆零售品牌多年来致力于科研与创新,凭借中信国际电讯CPC'智赋云网安'综合方案,协助构建安全、高效及灵活的数字基建底座,通过对网络及应用的动态感知、预测及智慧预警,助力实现「在上海、为中国、链全球」的优势价值,满足其中国内地以至世界各地消费者的需求。如欲了解更多有关从'技术赋能(+AI)'到'数据赋能(AI+)',请浏览:https://www.citictel-cpc.com/sc-hk/ict-miind中信国际电讯CPC简介中信国际电讯(信息技术)有限公司(「中信国际电讯CPC」)是中信国际电讯集团有限公司(香港交易所股份代号:1883)的全资附属公司,公司一直矢志透过先进技术及旗舰解决方案,包括TrueCONNECT™专用网络服务、TrustCSI™信息安全解决方案、DataHOUSE™全球统一云数据中心解决方案及SmartCLOUD™云端运算解决方案,为全球跨国企业提供综合数码解决方案, 满足不同行业的ICT服务需求。凭借「创新‧不断」的服务理念,中信国际电讯CPC积极利用创新技术,提炼'技术赋能',将人工智能、扩增实境、大数据,物联网和其他尖端新兴技术,融合深度学习及智能数据分析技术,转化为'数据赋能'生成式AI+应用,重塑企业智能营运之旅。中信国际电讯CPC以「服务在地,连接全球」优势,承诺为客户提供优质的一站式ICT服务。全球化网络资源连接近170个服务据点、60多个SDWAN 网关;21个云服务中心、30多个数据中心及3个全天候运作的安全运作中心,服务遍布约160个国家和地区,无缝连接亚洲、欧美、非洲、中东以及中亚等地区 。透过全球化服务布局,多年不断深耕各个行业与领域经验,一系列国际标准服务认证(SD-WAN Ready, ISO 9001、14001、20000、27001 及27017),确保为企业提供国际化标准及服务资源,专业的在地服务及交付能力,同时,优质的客户体验和服务质量,成为领先的综合信息智能化服务供应商。请浏览www.citictel-cpc.com 获取更多资讯。传媒查询:Catherine Yuen中信国际电讯CPC(852) 2170 7536电邮:catherine.yuen@citictel-cpc.com Copyright 2024 亚太商讯 via SeaPRwire.com.
More

Everest Medicines’ Stock Price Rises by 20% as Profit Potential Drives Valuation Recovery

HONG KONG, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (1952.HK) closed today with a 20.46% increase, hitting a high of HKD 28.6. The company's stock price has been steadily rising since the release of its interim results, with today's trading volume reaching HKD 291 million. Market updates show that BOCOM International released a report assigning an 'outperform' rating to the Chinese pharmaceutical sector, with Everest Medicines being one of the key recommended stocks.Recently, the Hong Kong government released a policy address with numerous measures aimed at attracting overseas capital to Hong Kong, which has been a positive driver for the Hong Kong stock market. Additionally, negative sentiment in the innovative drug sector is gradually fading, and the market is now focusing on companies with profit potential and valuation recovery resilience.According to Everest Medicines' 2024 interim financial report, the company saw a significant revenue increase in the first half of the year, reaching RMB 302 million, representing a 158% growth compared to the second half of last year, marking the first time the company has achieved commercial profitability. The company's core products, Nefecon® and XERAVA® (the world's first-in-class fluorocycline antibiotic), have already been commercialized, with three products expected to be launched by the end of the year. In terms of innovative research and development, Everest Medicines owns an mRNA platform with full intellectual property rights and global benefits, dedicated to developing both preventive and therapeutic mRNA products. The company expects to achieve full-year sales of RMB 700 million by 2024 and aims to break even by the end of 2025.As BOCOM International released a report, it highlighted that innovative drug companies with abundant short-term catalysts, strong profit growth potential, or clear break-even timelines, along with significant valuation recovery potential, are worth close attention. Investors are also advised to focus on small and mid-sized innovative pharmaceutical companies whose market value diverges significantly from their fundamentals. These companies are expected to experience a strong rebound as liquidity improves.Over the past two months, Everest Medicines' stock has risen by over 65%. Recently, the unexpected adjustments in domestic monetary policy further energized capital markets. The continuous rise in both Hong Kong and mainland Chinese stock markets highlights the innovative drug sector as a key area of focus, given its long-term valuation bottoming and significant growth potential, making it a highly attractive investment in this market rally. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
The 15th Turkish-Arab Economic Forum (TAFF 2024) took place at the Four Seasons Bosphorus Hotel in Istanbul

The 15th Turkish-Arab Economic Forum (TAFF 2024) took place at the Four Seasons Bosphorus Hotel in Istanbul

ISTANBUL, October 18, 2024 - (ACN Newswire via SeaPRwire.com) - The 15th Turkish-Arab Economic Forum (TAFF 2024), aimed at deepening relations between Turkiye and the Gulf countries and defining joint strategies for the region, took place yesterday in Istanbul.The Forum saw the attendance of many key figures from the Gulf countries, including Kuwait's Minister of Finance Noora Suleiman Salem Al-Fassam, Iraq's Minister of Finance Taif Sami Mohammed, Egypt's Deputy Minister of Finance Ahmed Kouchouk, Tunisia's Minister of Economy and Planning Samir Abdelhafidh, Libya's Minister of Finance Dr Kalid Al-Mabrouk, President of the Turkish Investment Fund Baghdad Amreyev, Secretary General of the Egyptian Federation of Arab Chambers Dr Khaled Hanafy, Regional Director of the Saudi International Finance Corporation Fawaz Bilbeisi, Director of the World Bank GCC Cooperation Safaa El Tayeb El-Kogali, Partner at the UK's DWF Solomon Ebere, Board Member of the Qatar Chamber Mohamed Bin Ahmed Al Obaidly, and Vice President of International Business Development of the United Arab Emirates Khalid Al Marzooqi.Turkiye's Minister of Treasury and Finance Mehmet Simsek evaluated global and regional strategies.In his speech at the 15th Turkish-Arab Economic Forum, Minister of Treasury and Finance Mehmet Simsek highlighted the decline in inflation and the slowdown in monetary policies. He emphasized that global trade will continue in November, pointing out that while there are challenges, there are also opportunities in this process. Mehmet Simsek further noted that he expects an increase in cooperation across various sectors, emphasizing that partnerships in energy, manufacturing, technology, and machinery are crucial for realizing the region's potential and he expressed his support for diversification strategies.Dr. Erkan Kork stated that Turkiye and the Gulf countries could build a shared future.Speaking at the 15th Turkish-Arab Economic Forum, Dr. Erkan Kork, Chairman of the Board of BankPozitif, highlighted that the participating countries share the same geography, history, and values, and emphasized that joint steps would be stronger and more effective. He noted that building a shared future with the available know-how, technology, and investments is vital for unlocking the region's potential.BankPozitif Chairman Dr Erkan Kork at the 15th Turkish Arab Economic ForumExpressing pride in Turkiye's positioning as a fintech hub, Dr Erkan Kork predicted that Turkiye would play a leading role on the global stage in various fields in the near future. He also stressed the importance of forums, fairs and events like this for fostering relationships between the business world and governments of different countries.In his speech, Dr Erkan Kork pointed out that Turkiye is in a very strong position in terms of innovation and information technology, noting that while processing times in many sectors in Europe are long, they are much shorter in Turkiye. Dr. Erkan Kork also highlighted Turkiye's high level of competitiveness in recent years.At the forum, which had a high participation rate, Fatih Karahan, Governor of the Central Bank of the Republic of Turkiye, Burak Dagloglu, Member of the Board of Directors of the Turkiye Wealth Fund, and Rfat Hisarckloglu, President of the Union of Chambers and Commodity Exchanges of Turkiye, were also among the speakers.Source: BankPozitif, https://www.bankpozitif.com.trSait Inanc, +90533 722 49 69, info@bankpozitif.com.tr* This press release is issued through EuropeNewswire.Net (www.europenewswire.net) and distributed by EmailWire (www.emailwire.com) – the gloabal newswire that provide Press Release Distribution with Guaranteed Results™. Copyright 2024 ACN Newswire via SeaPRwire.com.
More

云顶新耀股价升两成 盈利潜力助力估值修复

香港, 2024年10月18日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀(1952.HK)今日收盘升20.46%,最高触及28.6港元,公司自公布中期业绩开始股价一路向好,今日成交额达2.91亿元。消息层面看到,交银国际发表报告称,予内地医药行业"领先"评级,其中重点推荐了云顶新耀等一众股票。近期香港政府发布施政报告,众多举措有助吸引海外资金来港,对港股市场有推动作用,另外创新药板块负面情绪逐渐褪去,市场开始关注有盈利潜力和估值具有修复弹性的创新药标的。根据云顶新耀2024年中期财报,公司上半年收入大幅增长至人民币3.02亿元,较去年下半年增长158%,并实现公司历史上的首次商业化盈利。目前,公司的核心产品耐赋康®和全球首个氟环素类抗菌药物依嘉®(XERAVA®)已实现商业化,预计到年底将有三款产品实现商业化上市。在创新研发方面,云顶新耀拥有一个具有全部智慧财产权及全球权益的mRNA平台,用来开发预防及治疗性的mRNA自研产品。公司预计于2024年实现全年人民币7亿元的销售目标,并力争在2025年底前实现现金盈亏平衡。交银国际最新发表报告表示,短期催化剂丰富、盈利高增长或盈亏平衡时间点明确、估值有较大修复弹性的创新药标的,以及市值与基本面偏离较大的中小型创新药企,流动性改善后的反弹弹性将十分可观。近两个月来,云顶新耀的股价一度累计涨超65%。消息面上,近期国内货币政策的超预期调整激发了资本市场的活力,港A两地股市持续上涨。其中,创新药板块因其长期估值筑底和极具增长潜力的特性,拥有较高的投资性价比,成为此轮行情中值得关注的重要方向之一。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More
China Medical System: First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area

China Medical System: First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area

SHENZHEN, CHINA, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product’s new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the "Hong Kong and Macau Medicine and Equipment Connect" policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in the Mainland of Greater Bay Area.In addition, on 24 September, the NDA for vitiligo indication of ruxolitinib cream has been accepted by the National Medical Products Administration of China (NMPA). In accordance with the relevant regulations of the drug real-world data application pilot program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”), CMS has conducted a real-world study on ruxolitinib cream in China. The results have shown positive efficacy, which is consistent with the key outcomes of global pivotal clinical studies. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Meanwhile, through the safety monitoring data of the Pilot Zone, no new safety events have been identified. Adverse events mostly had severity levels of grade 1 or 2. No adverse event (AE) leading to discontinuation or withdrawal, and no serious adverse event (SAE) related to the study drug occurred.If the Product is successfully approved for marketing in Mainland China, it will be the first prescription drug approved by NMPA for repigmentation in vitiligo, bringing this novel treatment hopes for Chinese vitiligo patients.Furthermore, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Pilot Zone on August 18, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. As of 30 June 2024, more than 3,200 patients have been treated with ruxolitinib cream in Boao Super Hospital.CMS has always been patient-oriented and innovation-driven based on clinical needs, continuously striving to improve drug accessibility. Benefited from the "Hong Kong and Macau Medicine and Equipment Connect" policy, ruxolitinib cream was approved for use in the Greater Bay Area and completed its first batch of prescriptions, shortening the time difference for Chinese vitiligo patients to use innovative drug and benefiting more domestic patients. Looking forward to the future, the Group will continuously strive to meet the unmet needs of Chinese patients, continuously explore novel drugs with international quality, and efficiently promote products’ clinical development and commercialization, so as to bring more quality pharmaceutical products through differentiated innovation-breakthrough, to safeguard the health and life-quality of patients.About ruxolitinib creamRuxolitinib cream (Opzelura), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older. As of now, it is the first and only treatment for repigmentation approved for use in the United States[1]. Ruxolitinib cream (Opzelura) is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[2]. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].On 2 December 2022, the Group through a subsidiary of the Company, a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases. In accordance with the License Agreement, the Group through CMS Skinhealth received an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The License Agreement commenced on its effective date and has a royalty term of ten years from the date of the commercial sale of the Product in the Territory (the “Royalty Term”). Upon the expiration of the Royalty Term, the License Agreement may be renewed for a period of ten years thereafter (the “Initial Extended Royalty Term”) as per certain conditions defined in the License Agreement. Upon the expiration of the Initial Extended Royalty Term, the License Agreement may be extended for a period otherwise agreed by both sides as per certain conditions defined in the License Agreement.Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. Opzelura and the Opzelura logo are registered trademarks of Incyte.About vitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million vitiligo patients in China[4]. Non-segmental vitiligo patients account for approximately 85% of them. Topical corticosteroids (TCS) and calcineurin inhibitors (CI) are used off-label for non-segmental vitiligo, however, these therapies have clinical deficiencies with long-term adverse reactions of long-term treatment or limited efficacy[5,6].About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference:1. Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older2. Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream3. Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura4. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-75. Consensus on the diagnosis and treatment of vitiligo (2021 version)6. Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, Vázquez-Martínez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
康哲药业:芦可替尼乳膏(白癜风)大湾区首批处方落地

康哲药业:芦可替尼乳膏(白癜风)大湾区首批处方落地

深圳, 2024年10月18日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司("康哲药业")欣然宣布,磷酸芦可替尼乳膏("芦可替尼乳膏"或"产品")在中山陈星海中西医结合医院、佛山复星禅诚医院、以及东莞松山湖东华医院为符合条件的白癜风患者开出大湾区首批处方。产品于2024年4月11日获得澳门政府药物监督管理局(ISAF)批准新药上市申请,随后通过"港澳药械通"政策,并于8月19日获得广东省药品监督管理局批准,正式落地粤港澳大湾区内地指定医疗机构,用于12岁及以上青少年和成人患者伴面部受累的非节段型白癜风的治疗,为相关适应症患者提供了全新治疗选择。此外,芦可替尼乳膏白癜风适应症新药上市许可申请已于9月24日获得中国国家药品监督管理局(NMPA)受理。根据海南博鳌乐城国际医疗旅游先行区药品真实世界数据应用试点程序有关规定,芦可替尼乳膏在中国开展真实世界研究,疗效积极,与境外关键临床研究结果一致。所有的次要疗效指标均显示出与主要疗效指标一致的获益趋势,且治疗时间越长,患者的白癜风治疗效果持续改善。同时利用了乐城先行区安全监测数据,未发现新的安全性事件。不良反应的严重程度大部分均为1级或2级,未发生导致停药或退出的不良事件(AE),未发生研究药物相关的严重不良事件(SAE)。若产品于中国大陆获批上市,其有望成为首个经NMPA批准用于白癜风复色的处方药,将为中国广大白癜风患者带来治疗新曙光。除上述进展外,产品此前于2023年8月12日获得海南省药监局批准临床急需进口,并于8月18日正式落地海南博鳌乐城国际医疗旅游先行区,用于12岁及以上青少年和成人患者伴面部受累的非节段型白癜风的局部治疗。受益于国家赋予海南自由贸易港、博鳌乐城国际医疗旅游先行区"先行先试"特许政策,中国白癜风患者可在博鳌超级医院先行申请使用产品并接受专家团队的治疗。截至2024年6月30日,已有超3,200例患者在博鳌超级医院使用芦可替尼乳膏进行治疗。康哲药业始终以患者为中心,以临床需求驱动创新,为提升药物可及性而持续努力。本次芦可替尼乳膏得益于"港澳药械通"政策支持,先行获批引入大湾区,并完成首批处方落地,缩短了中国白癜风患者使用创新药的用药时差,让更多国内白癜风患者获益。展望未来,康哲药业将继续为满足中国患者未尽之需而奋进,持续挖掘国际品质的新药、好药,高效推动产品临床开发和商业化发展,以差异化的创新突破为病患带来更多优质的医药产品,为守护患者健康生活和生命质量贡献力量。关于芦可替尼乳膏芦可替尼乳膏(Opzelura),为Incyte的JAK1/JAK2选择性抑制剂芦可替尼的创新乳膏制剂,已获得美国食品和药物管理局(FDA)批准用于12岁及以上非节段型白癜风患者的局部治疗。截至目前,芦可替尼乳膏是首个也是唯一一种在美国获批使用的白癜风复色产品[1]。此外,产品在美国获批用于传统外用处方疗法不可取或不能充分控制病情之12岁及以上非免疫功能低下的轻中度AD患者的局部短期和非持续性慢性治疗[2]。产品也于欧洲获批用于12岁及以上青少年及成人患者伴面部受累的非节段型白癜风的治疗[3]。康哲药业于2022年12月2日,通过其附属公司-康哲美丽与Incyte就用于治疗自身免疫性炎症皮肤病的芦可替尼乳膏制剂订立合作和许可协议("许可协议")。根据该等许可协议,康哲药业通过康哲美丽获得在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一国(印尼、菲律宾、越南、泰国、缅甸、马来西亚、柬埔寨、老挝、新加坡、东帝汶以及文莱)("区域")开发、注册及商业化产品的独家许可权利,以及在区域内生产产品的非独家许可权利。许可协议期限开始于许可协议生效日,自产品在区域内首次商业化销售之日起拥有十年的授权期限("授权期限")。授权期限届满后,根据许可协议约定的特定条件,许可协议期限可延长十年("初始延展授权期限")。初始延展授权期限届满后,根据许可协议约定的特定条件,双方可另行协商许可协议的延长期限。Incyte拥有产品的全球开发和商业化权利,产品在美国及欧洲以Opzelura的名称销售。Opzelura及其logo为Incyte的注册商标。关于白癜风白癜风是一种慢性自身免疫性疾病,其特征是皮肤色素脱失,其发病原因为产生色素的细胞即黑素细胞的缺失。据估算,中国白癜风患者约1,400万[4]。白癜风患者中约85%为非节段型白癜风。外用皮质类固醇(TCS)及钙调神经磷酸酶抑制剂(CI)均为非节段型白癜风的标签外用药,然而,这些现有外用药物疗法有长期用药的不良反应或疗效有限的临床痛点[5、6]。关于康哲药业康哲药业是一家链接医药创新与商业化,把控产品全生命周期管理的开放式平台型企业,致力于提供有竞争力的产品和服务,满足尚未满足的医疗需求。康哲药业专注于全球首创(FIC)及同类最优(BIC)的创新产品,并高效推进创新产品临床研究开发和商业化进程,赋能科研成果向诊疗实践的持续转化,造福患者。康哲药业聚焦专科领域,拥有被验证的商业化能力,广泛的渠道覆盖和多疾病领域专家资源,核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展,以巩固心脑血管/消化业务竞争力,并将皮肤医美、眼科业务独立运营,培育专科小领域的大龙头,提升专科规模效率。同时业务版图拓展至东南亚市场,着力成为全球药企进军东南亚市场的"桥头堡",助力康哲药业高质量持续健康发展。参考文献/资料:1.FDA批准信息可在FDA官网查询,网址:https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older2.FDA批准信息可在incyte官网查询,网址:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream3.EMA批准信息可在EMA官网查询,网址:https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura4.Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-75.《白癜风诊疗共识(2021版)》6.Kubelis-Lopez DE,Zapata-Salazar NA,Said-Fernandez SL, Sanchez-Dominguez CN,Salinas-Santander MA,Martinez-Rodriguez HG,Vazquez-Martinez OT,Wollina U,Lotti T,Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广,非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息,请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请,不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制,但康哲药业并无进行任何说明或保证、明述或暗示,或其他表述,对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述,该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证,存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测,康哲药业对该等第三方声明及预测不承担责任。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More
Participation in the Multilateral System Remains High as Performance Drops, New Index Finds

Participation in the Multilateral System Remains High as Performance Drops, New Index Finds

Washington, D.C., Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - Today marks the launch of the second edition of the Multilateralism Index from the International Peace Institute (IPI) and the Institute for Economics & Peace (IEP). The Index reveals that states remain engaged in the global multilateral system even as it increasingly struggles to address the crises it faces.Multilateralism Index 2024 ReportAn image of the front cover of the Multilateralism Index 2024 ReportKey resultsThe performance of the multilateral system declined across all five domains examined.Peace and security showed the steepest deterioration in performance, with the number of armed conflicts rising from 39 in 2013 to 55 in 2022.Climate action and human rights also saw significant declines in performance, despite increased engagement from member states.Participation in multilateral institutions has increased in most domains, even as performance has declined, indicating a shift from cooperation to contestation.Inclusivity improved across all domains, with steady growth in NGO engagement and women's representation in UN bodies.The Multilateralism Index 2024 presents a complex picture of global cooperation over the past decade, examining five crucial domains: Peace and Security, Human Rights, Climate Action, Public Health, and Trade. It reveals a contradiction: while participation in the multilateral system has largely held steady or even increased, its effectiveness in addressing global challenges has declined.Dr. Adam Lupel, IPI Vice President & COO said: "Over the past decade, we've witnessed a paradox in multilateralism. While participation in international institutions has largely held steady or even increased, the performance of the multilateral system in addressing global challenges has declined. This suggests a shift from cooperation to contestation at a time of transformation and rising global crises."The peace and security domain experienced the most significant deterioration in performance. Active armed conflicts increased from 39 in 2013 to 55 in 2022, with a notable rise in internationalized conflicts. The UN Security Council has seen more frequent use of the veto power, constraining its ability to respond to crises. However, states have not broadly pulled back from the UN peace and security architecture, and commitments in some areas, such as multilateral peacebuilding, have increased.Climate action presents another contradiction. Despite near-universal participation in the Paris Agreement and growing climate commitments, these commitments continue to fall short of necessary targets. Projections show an 8.8% increase in emissions by 2030, in stark contrast to the 43% decrease required to meet the critical 1.5°C target.The human rights domain exhibits a counterintuitive pattern. While engagement with UN human rights mechanisms has increased, global human rights protections have steadily declined. Most strikingly, members of the UN Human Rights Council consistently scored lower on human rights measures than the global average, indicating that many states are engaging less to advance human rights than to shape the direction of the system.Multilateral action on public health was significantly shaped by the COVID-19 pandemic, which reversed years of progress, particularly in areas such as childhood immunization. It also put the shortcomings of the global public health system in stark relief, spurring negotiations on an international pandemic agreement aimed at strengthening preparedness and response capabilities for future health crises.Trade is the one area where both performance and participation decreased. The paralysis of global trade negotiations and breakdown in adherence to global trade rules signal a shift away from multilateral approaches. This trend, combined with growing geopolitical tensions, creates challenges for global economic cooperation.Steve Killelea, Founder & Executive Chairman of IEP, commented: "The Multilateralism Index 2024 reveals a challenging trend: while engagement in global institutions has increased, their effectiveness has declined across key areas. There is a need to revitalize our multilateral system to address today's complex challenges."Despite these challenges, the Index highlights positive developments, particularly in the area of inclusivity. NGO engagement with the UN system has grown, and women's representation has increased across many UN bodies. However, the Global South remains underrepresented in many areas, suggesting that geographic inclusivity remains a work in progress.As the world contends with interconnected crises, from conflict to climate change, the Multilateralism Index 2024 provides valuable insights into the current state of global cooperation. It underscores the need for thoughtful reform to ensure that multilateral institutions can effectively address the complex challenges of the 21st century.Contact InformationMike KoslowskiIEP Senior Communications Advisormkoslowski@economicsandpeace.org+61418410531Related FilesMultilateralism Index 2024 - Full Press Release (1)Multilateralism Index 2024 - Full Press Release (1)SOURCE: International Peace Institute Copyright 2024 ACN Newswire via SeaPRwire.com.
More

达势股份-达美乐中国收益和利润双双增长 持续优化投资者结构

香港, 2024年10月18日 - (亚太商讯 via SeaPRwire.com) - 近期,政府推出了一系列刺激经济和提振消费信心的政策,推动股市反弹。消费股在第三季度表现出色,领涨市场。其中,达势股份-达美乐中国("达美乐中国"或"达势股份"或"公司")(1405.HK),作为达美乐比萨在中国大陆、中国香港特别行政区和中国澳门特别行政区的独家总特许经营商,进一步优化投资者结构,意在为股东创造长期丰厚回报。2024年第三季度,达势股份被纳入香港恒生综合指数成分股及沪港通、深港通,展现了其市场信誉和增长潜力,同时提升公司流动性。自2023年3月28日上市以来,截至2024年10月15日,公司股价已上涨逾60%,远超恒生综合指数的同期表现[1]。为了进一步优化投资者结构、增强交易流动性,近期达美乐比萨间接全资子公司Domino's Pizza LLC公布同意通过场外大手交易方式,将其持有的截至2024年10月17日的10,000,000股达美乐中国的股份,约占其已发行股本总额的7.66%,出售给其他机构投资者。此次股份出售之后,Domino's Pizza LLC仍保留达美乐中国已发行股本总额的6.21%,其剩余股份禁售期为90天。达美乐比萨将继续保持与达美乐中国之间稳固且持久的关系。本次交易将进一步提升达势股份的流动性,为其投资者结构注入新的活力。一些知名国际投资银行分析师对达势股份给出"买入"或"优于预期"评级,显示出对公司基本面和股票表现的信心。达势股份通过战略扩张、高效运营和高消费者满意度持续展现其强劲实力。公司的成功主要归功于其4D战略:高质量的门店开发(Development)、高质价比的美味比萨(Delicious Pizza at Value)、高效的外送体验(Delivery)和数字化能力(Digital)。这一全面的战略布局使公司能为不断增长的消费者群体稳定提供高质价比的比萨。自2021年至2023年,达势股份实现复合年均增长率(CAGR)37.6%。2024年上半年,收益高达人民币20.4亿元,报告净利润和经调整净利润(税后)首次实现双双转正。达势股份的"走深走广"战略在其增长中发挥了重要作用。截至2024年9月30日,达势股份在全国33个城市经营978家门店,今年已新开210家门店,展现出强劲的门店网络扩张势头。目前,净新增门店数、在建门店数及签约门店数总和已接近全年目标的100%。公司预计将在第四季度开设第1,000家门店,未来两年每年新增300至350家门店。强劲的业绩表现支持了达势股份门店网络扩张。截至2024年第三季度,在达美乐比萨全球超21,000家门店的首30日销售排行榜中,达美乐中国门店在榜单前30名中占据了28个席位。自2017年第三季度现任管理团队接任以来,达势股份已连续29个季度实现同店销售额增长(SSSG),无论行业如何表现,公司始终保持增长态势。同时,达势股份的全面数字化战略也起到了关键作用,增强了消费者黏性。截至9月,公司会员计划"达人荟"会员人数已突破2,170万。过去一年里,1,100万名新用户通过达美乐中国的官方网上订餐渠道[2]首次下单。展望未来,达势股份将继续推进扩张并优化运营,在中国这个潜力无限的比萨市场中,公司将通过持续不断的创新和优化,来实现稳健且可持续的利润增长。达势股份以其坚定不移的战略,已经建立起了一套坚实而有竞争力的运营体系,确保在日益激烈的竞争环境中保持行业领先地位。在未来的发展道路上,达势股份将进一步巩固其市场领导地位,通过不断提升产品质量、服务水平以及顾客体验,为消费者带来更多的价值。[1]以达势股份及香港恒生综合指数2023年3月28日及2024年10月15日收盘价为准。[2]官方网上订餐渠道:达美乐比萨中国官网/官方微信公众号及小程序/官方APP。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More

DPC Dash – Domino’s Pizza China Drives Sales and Profit Growth and Optimizes Shareholder Structure

HONG KONG, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - As recent economic stimulus measures by the government of China boost consumer confidence, and propel a rally in domestic stock markets, consumption stocks have been leading the surge, closing strong in the third quarter of 2024 strong. DPC Dash – Domino’s Pizza China, ("DPC Dash" or the "Company") (1405.HK), Domino's Pizza's exclusive master franchisee in the China Mainland, the Hong Kong Special Administrative Region of China, and the Macau Special Administrative Region of China, has further optimized shareholder structure to deliver long-term and significant value to shareholders.In the third quarter of 2024, the Company announced its inclusion in the Hong Kong Hang Seng Composite Index and the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs, underscoring its market credibility and growth potential. The inclusion in both a major index and stock connect programs offered more liquidity. As of October 15, 2024, the company’s stock price has surged over 60% since its IPO on March 28, 2023, significantly outperforming the Hang Seng Composite Index during the same period[i]. In order to further optimize shareholder structure and enhance the Company’s trading liquidity, Domino’s Pizza LLC, an indirect wholly-owned subsidiary of Domino’s Pizza, recently announced an agreement to sell an aggregate of 10,000,000 of the Company’s shares, or 7.66% of its total issued share capital as of October 17, 2024, to purchasers including institutional investors through off-market block trades. Following this share sale, Domino’s Pizza LLC retains 6.21% of total issued share capital with a lock-up period of 90 days for its remaining shares. The enduring relationship between DPC Dash and DPZ remains robust. The allocation is an opportunity for DPC Dash to further improve liquidity and bring new dynamics to its shareholder structure. Notable international banks have rated DPC Dash as “Buy” or “Outperform”, showing confidence in the company’s fundamentals and stock performance.DPC Dash continues to demonstrate its market prowess with strategic growth, operational efficiency and customer satisfaction. The Company’s remarkable success can be largely attributed to its effective 4D strategy of Development, Delicious pizza at value, Delivery, and Digital. This comprehensive approach has enabled the company to serve high-quality, value-for-money pizzas to a steadily growing customer base. From 2021 to 2023, DPC Dash realized a Compounded Annual Growth Rate (CAGR) of 37.6% in revenue. In the first half of 2024, revenue reached RMB2.04 billion while both reported and adjusted net profit after tax turned positive for the first time.The Company’s “Go Deeper, Go Broader” strategy has been instrumental in its growth. As of September 30, 2024, DPC Dash operates 978 stores across 33 cities, reflecting a robust expansion with 210 new stores opened year-to-date. The combined total of net new stores added this year, stores currently under construction, and stores with signed agreements has reached approximately 100% of the full-year opening target for 2024. It is confident in maintaining this strong expansion dynamic, with plans to open its 1000th store in the fourth quarter of 2024 and open 300 to 350 new stores annually in 2025 and 2026. The store network expansion is supported by strong performance metrics, including holding 28 of the top 30 positions for first 30-day sales among Domino’s global network of over 21,000 stores as of the end of the third quarter of 2024. Since the current management took the helm in the third quarter of 2017, DPC Dash has since achieved 29 consecutive quarters of positive same-store sales growth (SSSG) despite market and industrial turbulence. Meanwhile, the company’s digital initiatives played a crucial role in driving customer engagement and loyalty. The company’s loyalty program boasted 21.7 million members as of September 2024, with 11 million new customers placing their first orders in the past 12 months with Domino’s Pizza China.Looking ahead, DPC Dash remains focused on its expansion plans and operational enhancements, aiming for sustainable, profitable growth in China’s vast pizza market through continual innovation and optimization. The company’s resilient business model and strategic initiatives position it well for continued success in this competitive industry. The company will continue to strengthen its market position and add value to consumers by constantly enhancing product quality, service level, and customer experience.[i] Based on closed stock price of DPC Dash and HSCI of March 28, 2023 and October 15, 2024. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
VPBank Partners With CleverTap To Transform Vietnam’s Banking Experience

VPBank Partners With CleverTap To Transform Vietnam’s Banking Experience

San Francisco, CA & Hanoi, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - VPBank, one of Vietnam’s largest private banks, partners with CleverTap, the all-in-one customer engagement platform, to deepen understanding of customers and their aspirations and use the insights to deliver hyper-personalized experiences to users, at scale. VPBank aims to elevate customer experience and drive higher conversions on products and offers through highly targeted campaigns built on complex, real-time segmentation that quickly connects with customers. Through this association with CleverTap, VPBank’s objective is to improve engagement, deepen relationships and drive higher retention, while keeping costs low.Established in 1993, VPBank operates in a wide variety of businesses including retail banking, corporate banking, wealth management, and consumer finance. VPBank aims to become a top-ranking financial institution among joint stock commercial banks in Vietnam, in terms of business scale, market share, and service quality. Leveraging CleverTap’s AI/ML-powered capability suite, Clever.AI, VPBank will be able to hyper-personalize its engagement via multiple automation and journeys. It will enable a seamless and omnichannel onboarding experience for new users, driving higher success rates for key milestones such as registration and the first transaction. With the unified customer view on CleverTap, VPBank can identify high-intent users and target them with contextual and relevant offerings, achieving an increase in customer lifetime value.Varun Krishna, Head of Digital Marketing, VPBank said, “We’ve always strived to maintain our position as one of Vietnam’s leading financial institutions. In an increasingly competitive banking landscape, delivering personalized and meaningful customer experiences is paramount. Partnering with CleverTap empowers us to harness advanced AI-driven insights, enabling us to engage our customers more effectively and tailor our offerings to their unique needs across digital channels. This collaboration not only enhances our ability to connect with customers on a deeper level but also drives sustained growth and loyalty. Together, we are committed to setting new standards in customer engagement and positioning VPBank as the most trusted and preferred bank in Vietnam.”Mai Vo, Country Manager, CleverTap said, “Vietnam’s banking sector is at the precipice of a new era of growth. Our partnership with VPBank couldn’t be timed better. With a legacy of innovation and customer-centricity, VPBank has consistently set benchmarks in the Vietnamese banking industry. Their commitment to using technology for crafting exceptional customer experiences aligns perfectly with our vision. Together, with CleverTap’s state-of-the-art omnichannel platform, personalizing and enhancing customer engagement has never been more seamless. This partnership is not only a testament to CleverTap’s expertise in driving conversion and retention but also underscores VPBank’s leadership in propelling Vietnam's banking sector into a new era of excellence”About CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Domino’s, Levis, Jio, Papa John’s, Zomato, Kotak Bank, Air Asia, Carousell, TD Bank, and Tesco to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit clevertap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/ X: https://twitter.com/CleverTap Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications, CleverTap+91 9820900036sony@clevertap.com ASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2024 ACN Newswire via SeaPRwire.com.
More